Filing Flows › Emergent BioSolutions (EBS) › Guidance history
Emergent BioSolutions (EBS) guidance history: what it guided and what it reported
Emergent BioSolutions gave guidance in 3 earnings releases on file since Apr 30, 2026. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +32.0% against the guided midpoint. Its releases raised guidance once and lowered it once.
Revenue
Met or beat 1 of 1 periods (1 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q2 2026 | $170M–$185M (Apr 30, 2026) | $234M | above the range | +32.0% |
| FY2026 | $720M–$760M (Apr 30, 2026) → lowered $645M–$675M (Aug 5, 2026) → lowered $600M–$645M (Nov 2, 2026) | — | to be reported | — |
Adjusted gross margin
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 45.0%–47.0% (Apr 30, 2026) → lowered 42.0%–44.0% (Aug 5, 2026) → raised 45.0%–47.0% (Nov 2, 2026) | — | to be reported | — |
Interest expense
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $40.0M (Apr 30, 2026) → reaffirmed $40.0M (Aug 5, 2026) → lowered $38.0M (Nov 2, 2026) | — | to be reported | — |
Stock-based compensation
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $20.0M (Apr 30, 2026) → lowered $19.0M (Aug 5, 2026) → reaffirmed $19.0M (Nov 2, 2026) | — | to be reported | — |
Capital expenditures
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $17.0M (Apr 30, 2026) → reaffirmed $17.0M (Aug 5, 2026) → lowered $16.0M (Nov 2, 2026) | — | to be reported | — |
Depreciation & amortization
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $90.0M (Apr 30, 2026) → lowered $82.0M (Aug 5, 2026) → lowered $81.0M (Nov 2, 2026) | — | to be reported | — |
The latest quarter
Emergent BioSolutions, Q3 2026: revenue $110M (-52% year over year), operating margin -33.9%, net loss $32.7M, operating cash flow $100M. The chart follows the revenue to costs, profit and cash.
Questions
Does Emergent BioSolutions beat its guidance?
Emergent BioSolutions gave guidance in 3 earnings releases on file since Apr 30, 2026. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +32.0% against the guided midpoint.
How often does Emergent BioSolutions raise guidance?
Its earnings releases raised guidance once and lowered it once since Apr 30, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.